The kinetics and magnitude of tau aggregation were assessed with CDs. Both B-CDs-MH and B-CDs are potent inhibitors of tau aggregation, with IC50 values of 1.5 ± 0.3 and 1.6 ± 1.5 μg/mL, respectively. These findings have therapeutic significance for delivering MH to target AD pathology in the brain for enhanced efficacy. This evidence concerns the gene MAPT and Alzheimer disease.